Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Advanced Search

Search

You could also try: against (297), vs. (65)

MyelomaBortezomib IV DexamethasonePabinostat 28 day

Description: Chemotherapy Protocol MULTIPLE MYELOMA BORTEZOMIB (IV)-DEXAMETHASONE-PANOBINOSTAT (28 day) Regimen • Multiple Myeloma – Bortez
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/MyelomaBortezomib-IV-DexamethasonePabinostat-28-day.pdf

MyelomaBortezomib IV DexamethasonePabinostat 21day Ver1.1

Description: Chemotherapy Protocol MULTIPLE MYELOMA BORTEZOMIB (IV)-DEXAMETHASONE-PANOBINOSTAT (21 day) Regimen • Multiple Myeloma – Borte
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/MyelomaBortezomib-IV-DexamethasonePabinostat-21day-Ver1.1.pdf

Myeloma VCD (SC35) bortezomib (SC) cyclophosphamide dexamethasone 35 day

Description: Chemotherapy Protocol MULTIPLE MYELOMA VCD (SC-35) - BORTEZOMIB (SC)-CYCLOPHOSPHAMIDE-DEXAMETHASONE (35 day) Regimen Multiple Mye
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/Myeloma-VCD-SC35-bortezomib-SC-cyclophosphamide-dexamethasone-35-day.pdf

Myeloma VCD (IV35) bortezomib (IV) cyclophosphamide dexamethasone 35 day

Description: Chemotherapy Protocol MULTIPLE MYELOMA VCD (IV-35) - BORTEZOMIB (IV)-CYCLOPHOSPHAMIDE-DEXAMETHASONE (35 day) Regimen Multiple Mye
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/Myeloma-VCD-IV35-bortezomib-IV-cyclophosphamide-dexamethasone-35-day.pdf

Nivolumab Ver 1.1 skin

Description: Chemotherapy Protocol SKIN CANCER Nivolumab This regimen may require funding. Regimen Skin – Nivolumab Indicat
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Skincancer/NivolumabVer1.1.pdf

Nivolumab 480mg skin

Description: Chemotherapy Protocol SKIN CANCER Nivolumab (480mg-28 days) Regimen • Skin – Nivolumab (480mg-28 days) Indicat
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Skincancer/Nivolumab-480mg.pdf

Nivolumab 240mg skin

Description: Chemotherapy Protocol SKIN CANCER Nivolumab (240mg-14 days) Regimen • Skin – Nivolumab (240mg-14 days) Indicat
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Skincancer/Nivolumab-240mg.pdf

Binimetinib-Encorafenib

Description: Chemotherapy Protocol SKIN CANCER Binimetinib-Encorafenib Regimen • Skin – Binimetinib-Encorafenib Indication • Unresectable or metastati
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Skincancer/Binimetinib-Encorafenib.pdf

Lenvatinib(60kg or greater)

Description: Chemotherapy Protocol HEPATOCELLULAR CANCER LENVATINIB (60kg or greater) Regimen • Hepatocellular – Lenvatinib Indication • Lenv
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Hepatobiliary/Lenvatinib-60kg-or-greater-Ver1.pdf

Lenvatinib(59kg or less)

Description: Chemotherapy Protocol HEPATOCELLULAR CANCER LENVATINIB (59kg or less) Regimen • Hepatocellular – Lenvatinib Indication • Lenvati
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Hepatobiliary/Lenvatinib-59kg-or-less-.pdf

191 to 200 of 233

Previous … 18 19 20 21 22 … Next